These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9830800)

  • 1. A patient-oriented approach to treatment of myelodysplastic syndromes.
    Cazzola M; Anderson JE; Ganser A; Hellström-Lindberg E
    Haematologica; 1998 Oct; 83(10):910-35. PubMed ID: 9830800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of adult myelodysplastic syndromes.
    Hellström-Lindberg E
    Int J Hematol; 1999 Oct; 70(3):141-54. PubMed ID: 10561906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
    Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S;
    Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
    Cazzola M
    Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplantation strategies for the management of patients with myelodysplastic syndromes.
    Meletis J; Terpos E
    J BUON; 2009; 14(4):551-64. PubMed ID: 20148443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: the Brazilian experience in the past decade.
    Valera ET; Latorre Mdo R; Mendes WL; Seber A; Lee ML; de Paula MJ; Loggetto SR; Velloso E; Niero-Melo L; Lopes LF;
    Leuk Res; 2004 Sep; 28(9):933-9. PubMed ID: 15234570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in supportive care of myelodysplastic syndromes.
    Gordon MS
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):21-4. PubMed ID: 10530713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplantation in myelodysplastic syndromes.
    de Witte T; Suciu S; Brand R; Muus P; Kröger N
    Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current approaches of treatment for myelodysplastic syndrome (MDS)].
    Lewandowski K; Goździk J; Hansz J
    Acta Haematol Pol; 1995; 26(4):333-41. PubMed ID: 8571734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes.
    Miller KB
    Curr Treat Options Oncol; 2000 Apr; 1(1):63-9. PubMed ID: 12057062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome.
    Nakai K; Kanda Y; Fukuhara S; Sakamaki H; Okamoto S; Kodera Y; Tanosaki R; Takahashi S; Matsushima T; Atsuta Y; Hamajima N; Kasai M; Kato S
    Leukemia; 2005 Mar; 19(3):396-401. PubMed ID: 15674354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of pre-transplant debulking treatment in patients undergoing allogeneic stem cell transplantation for high-risk myelodysplastic syndrome].
    Gauthier J; Damaj G; Yakoub-Agha I
    Bull Cancer; 2015 Apr; 102(4):340-8. PubMed ID: 25799164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome].
    Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L
    Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.